In:
Heart, BMJ, Vol. 109, No. 18 ( 2023-09), p. 1387-1393
Kurzfassung:
Owing to the paucity of data, this study aimed to investigate sex differences in clinical features and prognosis of patients with cardiac sarcoidosis (CS). Methods This study was a secondary analysis of the ILLUstration of the Management and prognosIs of JapaNese PATiEnts with Cardiac Sarcoidosis registry—a retrospective multicentre registry that enrolled patients with CS between 2001 and 2017. The primary outcome was potentially fatal ventricular arrhythmia events (pFVAEs)—a composite of sudden cardiac death, sustained ventricular tachycardia lasting 〉 30 s, ventricular fibrillation or the requirement for implantable cardioverter defibrillator therapy. Results Of the 512 participants (mean age±SD 61.6±11.4 years), 329 (64.2%) were females. Both sexes had peak ages of 60–64 years at diagnosis. Male patients were younger and had a higher prevalence of coronary artery disease and lower left ventricular ejection fraction than female patients. During a median follow-up of 3 years (IQR 1.6–5.6), pFVAEs were observed in 99 patients, with males having a significantly higher risk than females (p=0.002). This association was retained even after adjustment for other risk factors for pFVAEs, including left ventricular ejection fraction (adjusted HR 1.80; 95% CI 1.08 to 3.01, p=0.025). Conclusion Approximately two-thirds of patients with CS were females, with a peak age of approximately 60 years at clinical diagnosis in both sexes; male patients were younger than female patients. Male patients had a significantly higher risk of pFVAEs than female patients. Trial registration number UMIN000034974.
Materialart:
Online-Ressource
ISSN:
1355-6037
,
1468-201X
DOI:
10.1136/heartjnl-2022-322243
Sprache:
Englisch
Verlag:
BMJ
Publikationsdatum:
2023
ZDB Id:
2378689-9
ZDB Id:
1475501-4
